BBI Solutions (BBI), Cardiff, UK, a manufacturer of raw materials and finished test platforms for the in vitro diagnostics market, has continued to invest in its portfolio of antibodies, and has recently announced the launch of 10 infectious disease markers, 3 inflammatory markers, 2 fertility markers, and an additional cardiac marker. All of BBI’s new antibodies are available for sampling and have either been tested in lateral-flow assays or enzyme-linked immunosorbent assays, and many are already being used in commercial assays. Also, the company offers a number of recommended matched pairs, which are designed to save time and money in customers’ screening processes.
BBI is in a rapid period of expansion and growth, with recent announcements of a £14 million investment into a global headquarters for the BBI Group and the recent acquisition of Maine Biotechnology Services. This further investment in the expansion of BBI’s antibody portfolio forms another part of the company’s growth plans, as it strives to meet the growing demands of its customers.
BBI’s new infectious disease markers include Campylobacter, E. coli O157, H. pylori, influenza A and B, and Legionella pneumophila. BBI has also released antibodies for three inflammatory markers, calprotectin, C-reactive protein, and IL-6; two fertility markers, AMH and estriol; and myoglobin antibodies as a cardiac marker.
James Steggles, BBI’s antibodies commercial manager says, “We are pleased to be able to offer this range of high-quality antibodies that test developers can use with confidence as part of their assay research and development programs, and as they aim to improve the diagnosis of key diseases and conditions.”
BBI’s mission is to deliver exceptional products and technologies that people rely on to enjoy a better quality of life. “We have selected these antibodies following requests from our customers,” adds James. “They also work towards achieving our mission and our growth plans.”
For more information, visit BBI Solutions.